نتایج جستجو برای: riluzole

تعداد نتایج: 631  

Journal: :Amyotrophic lateral sclerosis : official publication of the World Federation of Neurology Research Group on Motor Neuron Diseases 2011
Ettore Beghi Adriano Chiò Philippe Couratier Jesùs Esteban Orla Hardiman Giancarlo Logroscino Andrea Millul Douglas Mitchell Pierre-Marie Preux Elisabetta Pupillo Zorica Stevic Robert Swingler Bryan J Traynor Leonard H Van den Berg Jan H Veldink Stefano Zoccolella

Abstract Effective treatments for amyotrophic lateral sclerosis (ALS) have remained elusive. Only riluzole, a drug thought to affect glutamate metabolism, improves survival albeit to modest extent. Explanations for the negative results of therapeutic trials include a likely heterogeneity, both in disease susceptibility and pathogenic mechanisms, and faulty methodology of clinical trials. Furthe...

Journal: :Expert Opinion on Drug Metabolism & Toxicology 2008

Journal: :Indian Journal of Pharmaceutical Sciences 2013

Journal: :Cancer research 2007
Jin Namkoong Seung-Shick Shin Hwa Jin Lee Yarí E Marín Brian A Wall James S Goydos Suzie Chen

Recently, several laboratories have started to investigate the involvement of glutamate signaling in cancer. In previous studies, we reported on a transgenic mouse model that develops melanoma spontaneously. Subsequent studies in these mice identified that the aberrant expression of metabotropic glutamate receptor 1 (GRM1) in melanocytes played a critical role in the onset of melanoma. Confirma...

Journal: :Journal of neurophysiology 2013
Elsa Fritz Pamela Izaurieta Alexandra Weiss Franco R Mir Patricio Rojas David Gonzalez Fabiola Rojas Robert H Brown Rodolfo Madrid Brigitte van Zundert

Amyotrophic lateral sclerosis (ALS) is a devastating paralytic disorder caused by dysfunction and degeneration of motoneurons starting in adulthood. Recent studies using cell or animal models document that astrocytes expressing disease-causing mutations of human superoxide dismutase 1 (hSOD1) contribute to the pathogenesis of ALS by releasing a neurotoxic factor(s). Neither the mechanism by whi...

2014
Arne A Ittner Amadeus Gladbach Josefine Bertz Lisa S Suh Lars M Ittner

Hypersynchronicity of neuronal brain circuits is a feature of Alzheimer's disease (AD). Mouse models of AD expressing mutated forms of the amyloid-β precursor protein (APP), a central protein involved in AD pathology, show cortical hypersynchronicity. We studied hippocampal circuitry in APP23 transgenic mice using telemetric electroencephalography (EEG), at the age of onset of memory deficits. ...

Journal: :Journal of neurophysiology 2006
Jean-Charles Viemari Jan-Marino Ramirez

Pacemakers are found throughout the mammalian CNS. Yet, it remains largely unknown how these neurons contribute to network activity. Here we show that for the respiratory network isolated in transverse slices of mice, different functions can be assigned to different types of pacemakers and nonpacemakers. This difference becomes evident in response to norepinephrine (NE). Although NE depolarized...

Journal: :Cancer research 2014
Yu Wen Jiadong Li Jasmine Koo Seung-Shick Shin Yong Lin Byeong-Seon Jeong Janice M Mehnert Suzie Chen Karine A Cohen-Sola James S Goydos

Glutamate-triggered signal transduction is thought to contribute widely to cancer pathogenesis. In melanoma, overexpression of the metabotropic glutamate receptor (GRM)-1 occurs frequently and its ectopic expression in melanocytes is sufficient for neoplastic transformation. Clinical evaluation of the GRM1 signaling inhibitor riluzole in patients with advanced melanoma has demonstrated tumor re...

2012
Luc Dupuis Reinhard Dengler Michael T. Heneka Thomas Meyer Stephan Zierz Jan Kassubek Wilhelm Fischer Franziska Steiner Eva Lindauer Markus Otto Jens Dreyhaupt Torsten Grehl Andreas Hermann Andrea S. Winkler Ulrich Bogdahn Reiner Benecke Bertold Schrank Carsten Wessig Julian Grosskreutz Albert C. Ludolph

BACKGROUND Pioglitazone, an oral anti-diabetic that stimulates the PPAR-gamma transcription factor, increased survival of mice with amyotrophic lateral sclerosis (ALS). METHODS/PRINCIPAL FINDINGS We performed a phase II, double blind, multicentre, placebo controlled trial of pioglitazone in ALS patients under riluzole. 219 patients were randomly assigned to receive 45 mg/day of pioglitazone o...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید